Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Randomized, Double-blind, Placebo-controlled, Cross-over Study of Oral Deucrictibant Soft Capsule for On-Demand Treatment of Attacks in Adolescents and Adults with Hereditary Angioedema

Next Previous
Trial Profile

A Phase 3, Randomized, Double-blind, Placebo-controlled, Cross-over Study of Oral Deucrictibant Soft Capsule for On-Demand Treatment of Attacks in Adolescents and Adults with Hereditary Angioedema

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 23 Apr 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Deucrictibant (Primary)
  • Indications Hereditary angioedema
  • Focus Registrational; Therapeutic Use
  • Acronyms RAPIDe-3
  • Sponsors Pharvaris

Most Recent Events

  • 13 Jan 2025 According to Pharvaris media release, enrollment in RAPIDe-3, the pivotal Phase 3 study of deucrictibant for the on-demand treatment of HAE attacks, continuing as planned; topline data anticipated in 1Q2026
  • 16 Oct 2024 According to Pharvaris media release, RAPIDe-3 phase 3 trial design will be presented as an oral presentation by Prof. Michihiro Hide, M.D., Ph.D. on Sunday, Oct. 20, 13:30-14:45 JST at Japanese Society of Allergology (JSA), Kyoto, Japan, being held October 18-20, 2024.
  • 03 Oct 2024 According to Pharvaris media release, data from this study has been accepted and will be presented at the 2024 Global Angioedema Forum- HAEi Global Leadership Workshop, taking place in Copenhagen, Denmark, from Oct. 4-5, 2024.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top